Titanovo Logo
Back to Cell Types

RT-112Homo sapiens (Human)Cancer cell line

Also known as: RT112, RT 112

🤖 AI SummaryBased on 13 publications

Quick Overview

Human bladder cancer cell line with known mutations and drug resistance profiles.

Detailed Summary

RT-112 is a human bladder cancer cell line derived from a transitional cell carcinoma. It is characterized by specific genetic mutations, including those in the TERT promoter, which are associated with telomerase activation and cancer progression. This cell line has been used in studies to investigate drug resistance mechanisms, particularly to cisplatin and gemcitabine. RT-112 exhibits resistance to multiple chemotherapeutic agents, making it a valuable model for studying acquired resistance in bladder cancer. The cell line has also been utilized in research on the role of FGFR3-TACC3 fusion in mitotic defects and tumor progression. Its genomic profile includes alterations in key cancer-related genes, contributing to its utility in preclinical drug development and molecular studies.

Research Applications

Drug resistance studiesGenomic profilingFGFR3-TACC3 fusion researchTelomerase activation studies

Key Characteristics

TERT promoter mutationsResistance to cisplatin and gemcitabineFGFR3-TACC3 fusionGenomic alterations in cancer-related genes
Generated on 6/17/2025

Basic Information

Database IDCVCL_1670
SpeciesHomo sapiens (Human)
Tissue SourceUrinary bladder[UBERON:UBERON_0001255]

Donor Information

Age CategoryUnknown
SexFemale

Disease Information

DiseaseBladder carcinoma
LineageBladder/Urinary Tract
SubtypeBladder Urothelial Carcinoma
OncoTree CodeBLCA

DepMap Information

Source TypeDSMZ
Source IDACH-000473_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Arg248Gln (c.743G>A)UnspecifiedSomatic mutation acquired during proliferationPubMed=20575032
MutationSimpleTP53p.Ser183Ter (c.548C>G)Homozygous-PubMed=30737244
MutationSimpleTERTc.1-124C>T (c.228C>T) (C228T)UnspecifiedIn promoterfrom parent cell line Hep-G2
Gene fusionFGFR3FGFR3-TACC3--from parent cell line RT-4

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10
D13S317
13,14
D16S539
11,13
D18S51
15
D19S433
13,15
D21S11
27,30
D2S1338
17,24
D3S1358
15
D5S818
10,13
D7S820
11,12
D8S1179
13,15
FGA
23
Penta D
10
Penta E
12,16
TH01
7
TPOX
8,11
vWA
14,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

DOIPubMedPMC

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Nat. Commun. 10:3574.1-3574.11(2019).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Systematic review: characteristics and preclinical uses of bladder cancer cell lines.

Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.

Bladder Cancer 4:169-183(2018).

DOIPubMedPMC

FGFR3-TACC3 cancer gene fusions cause mitotic defects by removal of endogenous TACC3 from the mitotic spindle.

Sarkar S., Ryan E.L., Royle S.J.

Open Biol. 7:170080.1-170080.11(2017).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.

Tsang S.X., Cai Z.-M., Wu S., Dean M., Costello J.C., Theodorescu D.

Oncogene 36:35-46(2017).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics.

Limbart D.M., Rodel F., Wezel F., Haferkamp A., Cinatl J. Jr.

Transl. Oncol. 8:210-216(2015).

DOIPubMedPMC

The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.

Chanock S.J., Valencia A., Real F.X.

BMC Genomics 16:403.1-403.16(2015).

DOIPubMedPMC

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

DOIPubMedPMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOIPubMed

Identification of mutations in distinct regions of p85 alpha in urothelial cancer.

Knowles M.A.

PLoS ONE 8:E84411-E84411(2013).

DOIPubMedPMC

Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.

Hurst C.D., Platt F.M., Knowles M.A.

Eur. Urol. 65:367-369(2014).

DOIPubMed

Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.

Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.

Eur. Urol. 65:360-366(2014).

DOIPubMed

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOIPubMedPMC

Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro.

Knowles M.A.

Genes Chromosomes Cancer 43:315-328(2005).

DOIPubMed

Novel chromosome findings in bladder cancer cell lines detected with multiplex fluorescence in situ hybridization.

Young B.D., Oliver R.T.D.

Cancer Genet. Cytogenet. 135:139-146(2002).

DOIPubMed

Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines.

Coulter J., Kennedy W.J., Skilleter A., Habuchi T., Knowles M.A.

Genes Chromosomes Cancer 34:86-96(2002).

DOIPubMed

Short tandem repeat profiling provides an international reference standard for human cell lines.

Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).

DOIPubMedPMC

Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion.

Harris A.L.

Br. J. Cancer 84:558-564(2001).

DOIPubMedPMC

The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.

Stadler W.M., Olopade O.I.

Urol. Res. 24:239-244(1996).

DOIPubMed

Invasiveness of endometriotic cells in vitro.";

Gaetje R., Kotzian S., Herrmann G., Baumann R., Starzinski-Powitz A.

Lancet 346:1463-1464(1995).

DOIPubMed

Identity of some human bladder cancer cell lines.";

O'Toole C.M., Povey S., Hepburn P.J., Franks L.M.

Nature 301:429-430(1983).

DOIPubMed

Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines.

Franks L.M.

Cancer Res. 46:3630-3636(1986).

PubMed

Radiosensitive human tumour cell lines may not be recovery deficient.

Peacock J.H., Cassoni A.M., McMillan T.J., Steel G.G.

Int. J. Radiat. Biol. 54:945-953(1988).

DOIPubMed

Development and characterization of cisplatin-resistant human testicular and bladder tumour cell lines.

Masters J.R.W.

Eur. J. Cancer 26:742-747(1990).

DOIPubMed

Alkaline phosphatase activity in human bladder tumor cell lines.";

Benham F.J., Cottell D.C., Franks L.M., Wilson P.D.

J. Histochem. Cytochem. 25:266-274(1977).

DOIPubMed

Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas.

Marshall C.J., Franks L.M., Carbonell A.W.

J. Natl. Cancer Inst. 58:1743-1751(1977).

DOIPubMed

Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors.

Fogh J.

Natl. Cancer Inst. Monogr. 49:5-9(1978).

PubMed

Web Resources

faculty.washington.edusynapse.org